Tarlatamab (1) – Imdylltra®

Advanced small-cell lung cancer, previously treated

Characteristics

Start date 01.07.2026
Resolution 17.12.2026 – active procedure
INN Tarlatamab
Brand name Imdylltra®
Pharm. company Amgen GmbH
G-BA Procedure ID D-1340
Therapeutic area Oncological diseases Orphan
Reason for procedure Initial assessment

Associated procedures

Tarlatamab (1) Imdylltra® Amgen GmbH Oncological diseases Advanced small-cell lung cancer, previously treated n.d. active procedure Orphan


<< List of all resolutions